Sk Biopharmaceuticals Co Ltd
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, wh… Read more
Sk Biopharmaceuticals Co Ltd (326030) - Net Assets
Latest net assets as of September 2025: ₩689.46 Billion KRW
Based on the latest financial reports, Sk Biopharmaceuticals Co Ltd (326030) has net assets worth ₩689.46 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩1.03 Trillion) and total liabilities (₩340.50 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩689.46 Billion |
| % of Total Assets | 66.94% |
| Annual Growth Rate | 18.49% |
| 5-Year Change | 51.42% |
| 10-Year Change | N/A |
| Growth Volatility | 61.09 |
Sk Biopharmaceuticals Co Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Sk Biopharmaceuticals Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sk Biopharmaceuticals Co Ltd (2016–2024)
The table below shows the annual net assets of Sk Biopharmaceuticals Co Ltd from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩573.98 Billion | +78.84% |
| 2023-12-31 | ₩320.95 Billion | +1.39% |
| 2022-12-31 | ₩316.56 Billion | -28.73% |
| 2021-12-31 | ₩444.19 Billion | +17.18% |
| 2020-12-31 | ₩379.07 Billion | +3010.24% |
| 2019-12-31 | ₩-13.03 Billion | -122.22% |
| 2018-12-31 | ₩58.63 Billion | +24.10% |
| 2017-12-31 | ₩47.24 Billion | -68.01% |
| 2016-12-31 | ₩147.69 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sk Biopharmaceuticals Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 43226011600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩1.17 Trillion | 213.78% |
| Total Equity | ₩546.27 Billion | 100.00% |
Sk Biopharmaceuticals Co Ltd Competitors by Market Cap
The table below lists competitors of Sk Biopharmaceuticals Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nihon Unisys Ltd
MU:NIU
|
$1.90 Billion |
|
Emmi AG
PINK:EMLZF
|
$1.90 Billion |
|
CUSTOMERS BANCORP VTG DL1
F:334
|
$1.90 Billion |
|
Enterprise Financial Services
NASDAQ:EFSC
|
$1.90 Billion |
|
Getty Realty Corporation
NYSE:GTY
|
$1.89 Billion |
|
Adaro Andalan Indonesia Tbk
JK:AADI
|
$1.89 Billion |
|
TietoEVRY Corp
HE:TIETO
|
$1.89 Billion |
|
NAGOYA RAILROAD
F:59V
|
$1.89 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sk Biopharmaceuticals Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 283,686,371,110 to 546,273,129,340, a change of 262,586,758,230 (92.6%).
- Net income of 240,738,037,870 contributed positively to equity growth.
- Other factors increased equity by 21,848,720,360.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩240.74 Billion | +44.07% |
| Other Changes | ₩21.85 Billion | +4.0% |
| Total Change | ₩- | 92.56% |
Book Value vs Market Value Analysis
This analysis compares Sk Biopharmaceuticals Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 14.18x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 177.06x to 14.18x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩558.57 | ₩98900.00 | x |
| 2018-12-31 | ₩693.19 | ₩98900.00 | x |
| 2019-12-31 | ₩-154.00 | ₩98900.00 | x |
| 2020-12-31 | ₩4840.39 | ₩98900.00 | x |
| 2021-12-31 | ₩5671.93 | ₩98900.00 | x |
| 2022-12-31 | ₩4042.23 | ₩98900.00 | x |
| 2023-12-31 | ₩3622.46 | ₩98900.00 | x |
| 2024-12-31 | ₩6975.49 | ₩98900.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sk Biopharmaceuticals Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 44.07%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 43.96%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 1.90x
- Recent ROE (44.07%) is above the historical average (-58.34%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -20.56% | -33.76% | 0.46x | 1.31x | ₩-45.13 Billion |
| 2017 | -206.70% | -114.46% | 0.87x | 2.08x | ₩-102.37 Billion |
| 2018 | -235.54% | -12568.64% | 0.01x | 1.63x | ₩-143.96 Billion |
| 2019 | 0.00% | -57.75% | 0.89x | 0.00x | ₩-70.22 Billion |
| 2020 | -65.27% | -951.63% | 0.05x | 1.32x | ₩-285.32 Billion |
| 2021 | 14.60% | 15.49% | 0.65x | 1.45x | ₩20.43 Billion |
| 2022 | -44.05% | -56.64% | 0.37x | 2.10x | ₩-171.09 Billion |
| 2023 | -11.59% | -9.27% | 0.49x | 2.55x | ₩-61.25 Billion |
| 2024 | 44.07% | 43.96% | 0.53x | 1.90x | ₩186.11 Billion |
Industry Comparison
This section compares Sk Biopharmaceuticals Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sk Biopharmaceuticals Co Ltd (326030) | ₩689.46 Billion | -20.56% | 0.49x | $1.89 Billion |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |